Table 2. Meta-analysis of the association between PARP-1 Val762Ala polymorphism and cancer risk.
| No. of subjects cases/controls | n | VA+AA vs. VV | AA vs. VA+VV | AA vs. VV | VA vs. VV | A vs. V | ||||||
| OR (95% CI) | Phet | OR (95% CI) | Phet | OR (95% CI) | Phet | OR (95% CI) | Phet | OR (95% CI) | Phet | |||
| Total | 16783/23063 | 39 | 1.03 (0.95–1.11) | 0.000 | 1.10 (0.97–1.26) | 0.000 | 1.13 (0.98–1.31) | 0.000 | 1.02 (0.95–1.10) | 0.001 | 1.04 (0.97–1.11) | 0.000 |
| Controls in HWE | 15922/20290 | 36 | 1.01 (0.94–1.09) | 0.000 | 1.09 (0.95–1.29) | 0.000 | 1.11 (0.96–1.28) | 0.000 | 1.00 (0.94–1.08) | 0.001 | 1.03 (0.96–1.10) | 0.000 |
| Ethnicities | ||||||||||||
| Caucasian | 10300/11773 | 21 | 0.93 (0.83–1.03) | 0.000 | 0.95 (0.76–1.18) | 0.079 | 0.92 (0.78–1.08) | 0.111 | 0.94 (0.84–1.04) | 0.000 | 0.96 (0.87–1.05) | 0.000 |
| Asian | 6483/11290 | 18 | 1.17 (1.09–1.25)* | 0.249 | 1.09 (1.03–1.39)* | 0.000 | 1.28 (1.08–1.51)* | 0.000 | 1.12 (1.04–1.20)* | 0.805 | 1.12 (1.05–1.21)* | 0.001 |
| Cancer type | ||||||||||||
| Colorectal | 1407/2458 | 3 | 1.08 (0.93–1.25) | 0.122 | 1.14 (0.79–1.67) | 0.064 | 1.18 (0.76–1.85) | 0.039 | 1.05 (0.90–1.23) | 0.419 | 1.08 (0.88–1.31) | 0.032 |
| Cervical | 1065/1467 | 3 | 1.26 (1.06–1.50)* | 0.444 | 1.59 (0.82–3.07) | 0.011 | 1.68 (0.91–3.10) | 0.036 | 1.14 (0.95–1.36) | 0.252 | 1.31 (1.16–1.48)* | 0.201 |
| Lung | 1702/1717 | 3 | 1.16 (1.00–1.33)* | 0.234 | 1.32 (1.09–1.61)* | 0.487 | 1.42 (1.14–1.76)* | 0.326 | 1.10 (0.95–1.28) | 0.447 | 1.16 (1.05–1.28)* | 0.182 |
| Gastric | 1219/1935 | 4 | 1.33 (1.14–1.55)* | 0.222 | 1.22 (0.77–1.94) | 0.001 | 1.38 (0.84–2.26) | 0.002 | 1.28 (1.09–1.51)* | 0.742 | 1.19 (0.95–1.48) | 0.006 |
| Glioma | 1818/2943 | 4 | 0.78 (0.69–0.89)* | 0.907 | 1.06 (0.46–2.42) | 0.013 | 0.92 (0.48–1.78) | 0.071 | 0.79 (0.68–0.91)* | 0.302 | 0.84 (0.75–0.95)* | 0.414 |
| Bladder | 1978/1979 | 3 | 1.09 (0.86–1.39) | 0.083 | 0.96 (0.69–1.33) | 0.818 | 0.99 (0.70–1.40) | 0.850 | 1.10 (0.84–1.44) | 0.057 | 1.08 (0.96–1.22) | 0.159 |
| Breast | 2414/2507 | 4 | 0.94 (0.83–1.07) | 0.203 | 0.92 (0.71–1.19) | 0.852 | 0.89 (0.68–1.17) | 0.838 | 0.95 (0.84–1.08) | 0.176 | 0.95 (0.86–1.05) | 0.317 |
| Other | 4489/6391 | 11 | 1.02 (0.88–1.19) | 0.005 | 0.98 (0.78–1.22) | 0.075 | 0.99 (0.76–1.30) | 0.024 | 1.01 (0.89–1.15) | 0.048 | 1.02 (0.90–1.16) | 0.001 |
| Source of controls | ||||||||||||
| PB | 4882/6719 | 9 | 1.02 (0.87–1.19) | 0.001 | 1.17 (0.90–1.51) | 0.003 | 1.18 (0.88–1.59) | 0.001 | 1.03 (0.89–1.20) | 0.013 | 1.07 (0.94–1.22) | 0.000 |
| HB | 9164/12410 | 24 | 1.03 (0.93–1.13) | 0.002 | 1.12 (0.94–1.33) | 0.001 | 1.15 (0.95–1.39) | 0.001 | 1.01 (0.93–1.10) | 0.04 | 1.03 (0.95–1.12) | 0.000 |
| Mixed | 1921/3176 | 4 | 1.03 (0.79–1.34) | 0.01 | 0.98 (0.67–1.42) | 0.019 | 1.03 (0.69–1.55) | 0.02 | 1.03 (0.80–1.33) | 0.028 | 0.99 (0.80–1.23) | 0.002 |
| Genotyping method | ||||||||||||
| PCR-RFLP | 5098/6364 | 11 | 1.09 (0.93–1.27) | 0.000 | 1.29 (1.07–1.55)* | 0.008 | 1.34 (1.07–1.67)* | 0.002 | 1.03 (0.90–1.19) | 0.004 | 1.10 (0.98–1.24) | 0.000 |
| TaqMan | 6458/10147 | 14 | 1.02 (0.92–1.12) | 0.055 | 0.97 (0.85–1.12) | 0.866 | 1.0 (0.86–1.16) | 0.628 | 1.04 (0.96–1.12) | 0.118 | 1.00 (0.93–1.09) | 0.061 |
| MassARRAY | 2594/3739 | 6 | 0.89 (0.75–1.07) | 0.051 | 0.90 (0.71–1.13) | 0.134 | 0.93 (0.73–1.20) | 0.133 | 0.94 (0.76–1.15) | 0.063 | 0.93 (0.79–1.10) | 0.039 |
| Other | 2261/2330 | 6 | 1.16 (0.89–1.50) | 0.005 | 1.42 (0.73–2.74) | 0.000 | 1.44 (0.73–2.85) | 0.000 | 1.10 (0.87–1.40) | 0.031 | 1.18 (0.92–1.52) | 0.000 |
Phet: P-value of Q-test for heterogeneity test. The fixed-effects model was used when P-value for heterogeneity test >0.10; otherwise, the random-effects model was used.
*indicate significant difference.